d/l AP-5 drug
Evidence from:
primary |
all sources
Related entities (4)
| Subject | Relation | Object | p-value | Evidence |
|---|---|---|---|---|
| CNQX | interacts_with | d/l AP-5 | — | 1 |
| d/l AP-5 | associated_with | artificial cerebrospinal fluid (ACSF) | — | 1 |
| d/l AP-5 | associated_with | iPSCs | — | 1 |
| d/l AP-5 | targets | NMDA receptor | — | 1 |
Mentioned in (9)
Papers in which this entity is mentioned.
- PKA and Ube3a regulate SK2 channel trafficking to promote synaptic plasticity in hippocampus: Implications for Angelman Syndrome. (2020)
- Transient Potassium Channels: Therapeutic Targets for Brain Disorders. (2019)
- Mental Illnesses-Associated Fxr1 and Its Negative Regulator Gsk3β Are Modulators of Anxiety and Glutamatergic Neurotransmission. (2018)
- Sustained synchronized neuronal network activity in a human astrocyte co-culture system. (2016)
- Convergent translational evidence of a role for anandamide in amygdala-mediated fear extinction, threat processing and stress-reactivity. (2013)
- Hedgehog agonist therapy corrects structural and cognitive deficits in a Down syndrome mouse model. (2013)
- Moderate prenatal alcohol exposure reduces plasticity and alters NMDA receptor subunit composition in the dentate gyrus. (2013)
- Loss of GluN2B-containing NMDA receptors in CA1 hippocampus and cortex impairs long-term depression, reduces dendritic spine density, and disrupts learning. (2010)
- Repeated homotypic stress elevates 2-arachidonoylglycerol levels and enhances short-term endocannabinoid signaling at inhibitory synapses in basolateral amygdala. (2009)
Merged raw entities (3)
All extracted name/type variants the normalize job merged into this entity. Use this to spot wrong merges, or aliases that should be split off.
| Raw name | Type | Papers | Mentions |
|---|---|---|---|
| ap-5 | drug | 4 | 11 |
| d-ap5 | drug | 4 | 5 |
| d/l ap-5 | drug | 2 | 2 |